Association between GnRH analogue use and atopic diseases in patients with prostate cancer: A population-based retrospective cohort study

PURPOSE: Gonadotropin-releasing hormone (GnRH) analogues reduce testosterone levels to castration levels in patients with prostate cancer. However, the role of testosterone in atopic diseases has remained undefined. We aimed to investigate this role. MATERIALS AND METHODS: This retrospective cohort...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Sheng-Feng, Lin, Hsiu-Chen, Lee, Mei-Yu, Keller, Joseph Jordan, Wang, Li-Hsuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9000094/
https://www.ncbi.nlm.nih.gov/pubmed/35404960
http://dx.doi.org/10.1371/journal.pone.0266771
_version_ 1784685349806538752
author Lin, Sheng-Feng
Lin, Hsiu-Chen
Lee, Mei-Yu
Keller, Joseph Jordan
Wang, Li-Hsuan
author_facet Lin, Sheng-Feng
Lin, Hsiu-Chen
Lee, Mei-Yu
Keller, Joseph Jordan
Wang, Li-Hsuan
author_sort Lin, Sheng-Feng
collection PubMed
description PURPOSE: Gonadotropin-releasing hormone (GnRH) analogues reduce testosterone levels to castration levels in patients with prostate cancer. However, the role of testosterone in atopic diseases has remained undefined. We aimed to investigate this role. MATERIALS AND METHODS: This retrospective cohort study was conducted using the National Health Insurance Research Database (NHIRD). Patients with prostate cancer were categorized into two groups according to whether they received GnRH analogue treatment (study group I) or not (study group II), and men without prostate cancer and with no GnRH analogue use were defined to comprise the comparison group after their ages and index years were matched with group II. Cox proportional hazard models were used to assess the hazard ratio (HR) of atopic diseases. RESULTS: Group I, group II, and the comparison group comprised 663, 2,172, and 8,688 individuals, respectively. Group I had a significantly lower risk of atopic diseases (adjusted HR: 0.66, 95% CI, 0.49–0.89, p < 0.01) than did group II. A reduced risk of atopic diseases was found when GnRH analogues were prescribed for 2 months (adjusted HR 0.53, 95% CI, 0.29–0.97, p = 0.04) and 2–14 months (adjusted HR 0.66, 95% CI, 0.49–0.89, p = 0.007). No significant difference in the risk of atopic diseases between group II and the comparison group was observed. CONCLUSIONS: A decreased risk of atopic diseases was observed in patients with prostate cancer treated with GnRH analogues. Further studies are warranted to verify the association between testosterone levels and atopic diseases.
format Online
Article
Text
id pubmed-9000094
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-90000942022-04-12 Association between GnRH analogue use and atopic diseases in patients with prostate cancer: A population-based retrospective cohort study Lin, Sheng-Feng Lin, Hsiu-Chen Lee, Mei-Yu Keller, Joseph Jordan Wang, Li-Hsuan PLoS One Research Article PURPOSE: Gonadotropin-releasing hormone (GnRH) analogues reduce testosterone levels to castration levels in patients with prostate cancer. However, the role of testosterone in atopic diseases has remained undefined. We aimed to investigate this role. MATERIALS AND METHODS: This retrospective cohort study was conducted using the National Health Insurance Research Database (NHIRD). Patients with prostate cancer were categorized into two groups according to whether they received GnRH analogue treatment (study group I) or not (study group II), and men without prostate cancer and with no GnRH analogue use were defined to comprise the comparison group after their ages and index years were matched with group II. Cox proportional hazard models were used to assess the hazard ratio (HR) of atopic diseases. RESULTS: Group I, group II, and the comparison group comprised 663, 2,172, and 8,688 individuals, respectively. Group I had a significantly lower risk of atopic diseases (adjusted HR: 0.66, 95% CI, 0.49–0.89, p < 0.01) than did group II. A reduced risk of atopic diseases was found when GnRH analogues were prescribed for 2 months (adjusted HR 0.53, 95% CI, 0.29–0.97, p = 0.04) and 2–14 months (adjusted HR 0.66, 95% CI, 0.49–0.89, p = 0.007). No significant difference in the risk of atopic diseases between group II and the comparison group was observed. CONCLUSIONS: A decreased risk of atopic diseases was observed in patients with prostate cancer treated with GnRH analogues. Further studies are warranted to verify the association between testosterone levels and atopic diseases. Public Library of Science 2022-04-11 /pmc/articles/PMC9000094/ /pubmed/35404960 http://dx.doi.org/10.1371/journal.pone.0266771 Text en © 2022 Lin et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Lin, Sheng-Feng
Lin, Hsiu-Chen
Lee, Mei-Yu
Keller, Joseph Jordan
Wang, Li-Hsuan
Association between GnRH analogue use and atopic diseases in patients with prostate cancer: A population-based retrospective cohort study
title Association between GnRH analogue use and atopic diseases in patients with prostate cancer: A population-based retrospective cohort study
title_full Association between GnRH analogue use and atopic diseases in patients with prostate cancer: A population-based retrospective cohort study
title_fullStr Association between GnRH analogue use and atopic diseases in patients with prostate cancer: A population-based retrospective cohort study
title_full_unstemmed Association between GnRH analogue use and atopic diseases in patients with prostate cancer: A population-based retrospective cohort study
title_short Association between GnRH analogue use and atopic diseases in patients with prostate cancer: A population-based retrospective cohort study
title_sort association between gnrh analogue use and atopic diseases in patients with prostate cancer: a population-based retrospective cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9000094/
https://www.ncbi.nlm.nih.gov/pubmed/35404960
http://dx.doi.org/10.1371/journal.pone.0266771
work_keys_str_mv AT linshengfeng associationbetweengnrhanalogueuseandatopicdiseasesinpatientswithprostatecancerapopulationbasedretrospectivecohortstudy
AT linhsiuchen associationbetweengnrhanalogueuseandatopicdiseasesinpatientswithprostatecancerapopulationbasedretrospectivecohortstudy
AT leemeiyu associationbetweengnrhanalogueuseandatopicdiseasesinpatientswithprostatecancerapopulationbasedretrospectivecohortstudy
AT kellerjosephjordan associationbetweengnrhanalogueuseandatopicdiseasesinpatientswithprostatecancerapopulationbasedretrospectivecohortstudy
AT wanglihsuan associationbetweengnrhanalogueuseandatopicdiseasesinpatientswithprostatecancerapopulationbasedretrospectivecohortstudy